中药辅助紫杉醇-顺铂方案经导管动脉灌注化疗治疗不可切除非小细胞肺癌的临床研究  

Transcatheter arterial infusion chemotherapy by using traditional Chinese medicine-assisted TP regimen for the treatment of inoperable non-small cell lung cancer: a clinical study

作　　者：黄坤林 张秀美 宋伟祥[1] 刘玉金[1] HUANG Kunlin;ZHANG Xiumei;SONG Weixiang;LIU Ynjin(Department of Interventional Radiology,Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China)

机构地区：[1]上海中医药大学附属岳阳中西医结合医院肿瘤介入科,200437 [2]上海市第四人民医院

出　　处：《介入放射学杂志》2021年第2期136-139,共4页Journal of Interventional Radiology

基　　金：上海市科委“科技创新行动计划”医学创新研究专项项目(20Y11913900)。

摘　　要：目的评价中药辅助紫杉醇-顺铂(TP)方案经导管动脉灌注化疗(TAI)治疗不可切除非小细胞肺癌(NSCLC)的临床价值。方法随访连续103例NSCLC患者,按治疗方法不同分为接受TAI治疗的西医组和接受中药辅助TAI治疗的中西医组。结果 103例肺癌患者西医组71例,中西医组32例。西医组的平均生存期为10.5个月,中西医组的平均生存期为15.5个月;西医组的中位生存期为7.0个月,中西医组的中位生存期为12.0个月。西医组的6个月、1年、2年生存率分别为64.8%、26.8%、8.5%,中西医组分别为71.9%、43.8%、18.8%。中西医组的总生存期、平均生存期、中位生存期及生存率(6个月、1年和2年生存率)均高于西医组,差异有统计学意义(P<0.05)。结论中药辅助TAI治疗能延长不可切除NSCLC患者的生存期,提高患者的生存率,改善患者的生存质量,并降低患者的介入化疗后的不良反应,是一种安全有效的肺癌治疗模式。Objective To evaluate the clinical value of transcatheter arterial infusion chemotherapy(TAI) by using traditional Chinese medicine-assisted(TCM-assisted) paclitaxel-cisplatin(TP) regimen in treating inoperable non-small cell lung cancer(NSCLC). Methods A total of consecutive 103 patients with inoperable NSCLC, who received TAI, were enrolled in this study. According to the therapeutic scheme, the patients were divided into Western medicine group(n=71) and TCM-assisted TP group(n=32). Results In Western medicine group and TCM-assisted TP group, the mean survival time was 10.5 months and 15.5 months respectively, the median survival time was 7.0 months and 12.0 months respectively. The 6-month, one-year and 2-year survival rates in Western medicine group were 64.8%, 26.8% and 8.5% respectively, which were71.9%, 43.8% and 18.8% respectively in TCM-assisted TP group. All the overall survival time, mean survival time, median survival time, the 6-month, one-year and 2-year survival rates in TCM-assisted TP group were higher than those in Western medicine group, the differences between the two groups were statistically significant(P<0.05). Conclusion For the treatment of patients with inoperable NSCLC, TAI by using TCMassisted TP can prolong survival time, improve survival rate and quality of life, and reduce the adverse reactions after interventional chemotherapy. Therefor, it is a safe and effective therapeutic method for inoperable NSCLC.

关 键 词：非小细胞肺癌 清肺消积方 动脉灌注化疗 生存期 

分 类 号：R734[医药卫生—肿瘤]